Cargando…

The pharmacokinetics of anthocyanins and their metabolites in humans

BACKGROUND AND PURPOSE: Anthocyanins are phytochemicals with reported vasoactive bioactivity. However, given their instability at neutral pH, they are presumed to undergo significant degradation and subsequent biotransformation. The aim of the present study was to establish the pharmacokinetics of t...

Descripción completa

Detalles Bibliográficos
Autores principales: de Ferrars, R M, Czank, C, Zhang, Q, Botting, N P, Kroon, P A, Cassidy, A, Kay, C D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080980/
https://www.ncbi.nlm.nih.gov/pubmed/24602005
http://dx.doi.org/10.1111/bph.12676
_version_ 1782324043843633152
author de Ferrars, R M
Czank, C
Zhang, Q
Botting, N P
Kroon, P A
Cassidy, A
Kay, C D
author_facet de Ferrars, R M
Czank, C
Zhang, Q
Botting, N P
Kroon, P A
Cassidy, A
Kay, C D
author_sort de Ferrars, R M
collection PubMed
description BACKGROUND AND PURPOSE: Anthocyanins are phytochemicals with reported vasoactive bioactivity. However, given their instability at neutral pH, they are presumed to undergo significant degradation and subsequent biotransformation. The aim of the present study was to establish the pharmacokinetics of the metabolites of cyanidin-3-glucoside (C3G), a widely consumed dietary phytochemical with potential cardioprotective properties. EXPERIMENTAL APPROACH: A 500 mg oral bolus dose of 6,8,10,3′,5′-(13)C(5)-C3G was fed to eight healthy male participants, followed by a 48 h collection (0, 0.5, 1, 2, 4, 6, 24, 48 h) of blood, urine and faecal samples. Samples were analysed by HPLC-ESI-MS/MS with elimination kinetics established using non-compartmental pharmacokinetic modelling. KEY RESULTS: Seventeen (13)C-labelled compounds were identified in the serum, including (13)C(5)-C3G, its degradation products, protocatechuic acid (PCA) and phloroglucinaldehyde (PGA), 13 metabolites of PCA and 1 metabolite derived from PGA. The maximal concentrations of the phenolic metabolites (C(max)) ranged from 10 to 2000 nM, between 2 and 30 h (t(max)) post-consumption, with half-lives of elimination observed between 0.5 and 96 h. The major phenolic metabolites identified were hippuric acid and ferulic acid, which peaked in the serum at approximately 16 and 8 h respectively. CONCLUSIONS AND IMPLICATIONS: Anthocyanins are metabolized to a structurally diverse range of metabolites that exhibit dynamic kinetic profiles. Understanding the elimination kinetics of these metabolites is key to the design of future studies examining their utility in dietary interventions or as therapeutics for disease risk reduction.
format Online
Article
Text
id pubmed-4080980
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-40809802015-01-15 The pharmacokinetics of anthocyanins and their metabolites in humans de Ferrars, R M Czank, C Zhang, Q Botting, N P Kroon, P A Cassidy, A Kay, C D Br J Pharmacol Research Papers BACKGROUND AND PURPOSE: Anthocyanins are phytochemicals with reported vasoactive bioactivity. However, given their instability at neutral pH, they are presumed to undergo significant degradation and subsequent biotransformation. The aim of the present study was to establish the pharmacokinetics of the metabolites of cyanidin-3-glucoside (C3G), a widely consumed dietary phytochemical with potential cardioprotective properties. EXPERIMENTAL APPROACH: A 500 mg oral bolus dose of 6,8,10,3′,5′-(13)C(5)-C3G was fed to eight healthy male participants, followed by a 48 h collection (0, 0.5, 1, 2, 4, 6, 24, 48 h) of blood, urine and faecal samples. Samples were analysed by HPLC-ESI-MS/MS with elimination kinetics established using non-compartmental pharmacokinetic modelling. KEY RESULTS: Seventeen (13)C-labelled compounds were identified in the serum, including (13)C(5)-C3G, its degradation products, protocatechuic acid (PCA) and phloroglucinaldehyde (PGA), 13 metabolites of PCA and 1 metabolite derived from PGA. The maximal concentrations of the phenolic metabolites (C(max)) ranged from 10 to 2000 nM, between 2 and 30 h (t(max)) post-consumption, with half-lives of elimination observed between 0.5 and 96 h. The major phenolic metabolites identified were hippuric acid and ferulic acid, which peaked in the serum at approximately 16 and 8 h respectively. CONCLUSIONS AND IMPLICATIONS: Anthocyanins are metabolized to a structurally diverse range of metabolites that exhibit dynamic kinetic profiles. Understanding the elimination kinetics of these metabolites is key to the design of future studies examining their utility in dietary interventions or as therapeutics for disease risk reduction. Blackwell Publishing Ltd 2014-07 2014-06-10 /pmc/articles/PMC4080980/ /pubmed/24602005 http://dx.doi.org/10.1111/bph.12676 Text en © 2014 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Papers
de Ferrars, R M
Czank, C
Zhang, Q
Botting, N P
Kroon, P A
Cassidy, A
Kay, C D
The pharmacokinetics of anthocyanins and their metabolites in humans
title The pharmacokinetics of anthocyanins and their metabolites in humans
title_full The pharmacokinetics of anthocyanins and their metabolites in humans
title_fullStr The pharmacokinetics of anthocyanins and their metabolites in humans
title_full_unstemmed The pharmacokinetics of anthocyanins and their metabolites in humans
title_short The pharmacokinetics of anthocyanins and their metabolites in humans
title_sort pharmacokinetics of anthocyanins and their metabolites in humans
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080980/
https://www.ncbi.nlm.nih.gov/pubmed/24602005
http://dx.doi.org/10.1111/bph.12676
work_keys_str_mv AT deferrarsrm thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT czankc thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT zhangq thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT bottingnp thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT kroonpa thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT cassidya thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT kaycd thepharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT deferrarsrm pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT czankc pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT zhangq pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT bottingnp pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT kroonpa pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT cassidya pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans
AT kaycd pharmacokineticsofanthocyaninsandtheirmetabolitesinhumans